Cancer Immunotherapy

What Cancer Immunotherapy does

The Association for Cancer Immunotherapy CIMT e.V. (CIMT) is a non-profit association founded in Mainz, Germany in fall 2002 to serve as an information and education platform for immunological cancer therapy. CIMT organizes Europe's leading annual cancer immunotherapy meeting (the 23rd edition scheduled for May 11-13, 2026 at the Rheingoldhalle Congress Center in Mainz), drawing 700-870 international participants from 30+ countries, alongside supporting educational programs including CIMT Academy, Summer School, Winter School, and a Cancer Cell Therapy Summit. Beyond the annual meeting, CIMT operates two standing working groups: the CIMT Immunoguiding Program (CIP), which develops standards for reproducible immune monitoring in clinical trials, and the Regulatory Research Group (RRG), which addresses the regulatory environment for new immunotherapies. CIMT also stewards the MIATA (Minimal Information About T cell Assays) reporting framework and publishes peer-reviewed meeting reports in Human Vaccines & Immunotherapeutics.

CIMT's service portfolio targets three horizontal segments: academic researchers and scientists, industry professionals from pharmaceutical and biotechnology companies, and clinicians and physicians specializing in oncology. Functional offerings include plenary sessions, poster presentations, short talks, an industry exhibition, and recognition programs (a biennial €10,000-endowed Lifetime Achievement Award and annual poster awards for early-career researchers). Distribution relies on in-person attendance in Mainz supplemented by virtual and on-demand meeting platforms, year-round newsletter engagement, and earned media coverage through partnerships with ACIR and SITC. Core technology is administrative rather than proprietary: CIMT does not develop or commercialize technology products, and its operations are supported by a small staff (1-10 employees) and an Executive Board led by President Prof. Dr. Özlem Türeci.

CIMT operates as a registered German eingetragener Verein (e.V.) and does not have a traditional commercial revenue model. Revenue is generated through three streams: tiered conference registration fees (€350-€995 across member/non-member and academic/industry/postdoc/student segments), corporate sponsorships and exhibitor fees from pharmaceutical and biotechnology companies (including Diamond, Platinum, Silver, and event-specific tiers anchored by BioNTech and TRON), and donations and financial support from members and supporters. Marketing channels are concentrated around the annual meeting, the cimt.eu website, LinkedIn, and email newsletters, with community engagement maintained through the standing working groups. CIMT holds no patents, has no subsidiaries, and operates independently with no parent company.

Name

Cancer Immunotherapy

Legal name

Association for Cancer Immunotherapy CIMT e.V.

Website

https://cimt.eu

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

1–10 employees

Short description

The Association for Cancer Immunotherapy (CIMT) is a Mainz-based non-profit association that runs Europe's leading annual cancer immunotherapy conference and education platform, serving academic researchers, clinicians, and pharmaceutical industry professionals through meetings, working groups, and the MIATA T-cell assay reporting framework.

Ownership category

akta.pro rank

Headquarters

HQ city

Mainz

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others, Infrastructure

Revenue model

1. Conference Registration Fees: Revenue generated from conference registration fees for the annual CIMT Annual Meeting, with tiered pricing for academic/government, industry, postdoc, and student attendees.
2. Sponsorships and Exhibitor Fees: Corporate sponsorships and industry exhibitor fees from pharmaceutical and biotechnology companies participating in the annual meeting.
3. Donations and Financial Support: The organization operates as a non-profit and depends on donations and financial support from members and supporters.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

CIMT is a non-profit association that operates an education and collaboration platform for cancer immunotherapy research and translation. It hosts Europe's leading annual scientific meeting on cancer immunotherapy in Mainz, Germany, along with additional conferences (CICON, Cancer Cell Therapy Summit), working groups on immunomonitoring (CIP) and regulatory research (RRG), seasonal schools, and an academy program. The association also maintains the MIATA standardized reporting framework for T-cell assays, publishes meeting reports in Human Vaccines & Immunotherapeutics, and recognizes researchers through Lifetime Achievement and Poster Awards.

Product overview

The Association for Cancer Immunotherapy (CIMT) is a non-profit organization founded in 2002 as an information and education platform for immunological cancer therapy. CIMT functions as a professional association rather than a product company, offering a portfolio of educational and networking services centered on cancer immunotherapy. The core offerings include the CIMT Annual Meeting (Europe's largest cancer immunotherapy conference), specialized Working Groups (CIP for immunoguiding standards and RRG for regulatory research), the CIMT Academy for education, the MIATA reporting framework for T-cell assays, scientific publications and meeting reports, awards (Lifetime Achievement Award and Poster Awards), and seasonal schools. CIMT also organizes the CICON international conference and publishes a regular newsletter.

Differentiator

Problem solved

Functional benefit

Products and services

• CIMT Annual Meeting Europe's premier annual conference on cancer immunotherapy research and development, held at the Rheingoldhalle Congress Center in Mainz, Germany. Features plenary sessions, poster presentations, short talks, and an industry exhibition for researchers, clinicians, industry professionals, and regulatory authorities.
• CIMT Working Groups (CIP and RRG) Specialized community-driven working groups for cancer immunotherapy professionals. The CIMT Immunoguiding Program (CIP) develops standards for consistent and reproducible immune monitoring in clinical trials, while the Regulatory Research Group (RRG) addresses the regulatory environment for new immunotherapies.
• CIMT Academy Educational platform for scientists and clinicians active in cancer immunotherapy research and translation, supporting professional development in the field.
• CIMT Summer School and Winter School Seasonal educational programs providing training and professional development in cancer immunotherapy for early-career researchers and clinicians.
• CICON (Cancer Immunotherapy Conference) International cancer immunotherapy conference co-organized with the Cancer Research Institute (CRI) and the European Network for Cancer Immunotherapy (ENCI), bringing together global researchers and clinicians.
• Cancer Cell Therapy Summit

Quantifiable outcome

• Annual meetings consistently draw 700-800+ international participants from 30+ countries
• +2 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

14 partnerships are on record, tiered core, major and minor.

• BioNTech SEcoreGTM or Marketing PartnerDiamond sponsor of 23rd CIMT Annual Meeting (2026). As a leading mRNA therapeutics company, BioNTech's sponsorship supports Europe's premier cancer immunotherapy conference.
• TRON - Translational OncologycoreGTM or Marketing PartnerPlatinum sponsor of 23rd CIMT Annual Meeting (2026). TRON is a translational oncology research organization in Mainz, Germany, co-founded by Ugur Sahin.
• Boehringer IngelheimmajorGTM or Marketing PartnerSilver sponsor of 23rd CIMT Annual Meeting (2026). Major pharmaceutical company with cancer immunotherapy research programs.
• Leica MicrosystemsmajorGTM or Marketing PartnerSilver sponsor of 23rd CIMT Annual Meeting (2026). Provides microscopy and imaging technologies relevant to cancer research.
• 10x GenomicsmajorGTM or Marketing PartnerSilver sponsor of 23rd CIMT Annual Meeting (2026). Provides single-cell analysis and genomics technologies for cancer immunotherapy research.
• Immatics BiotechnologiescoreGTM or Marketing PartnerSilver sponsor and Poster Exhibition Sponsor of 23rd CIMT Annual Meeting (2026). Long-time supporter of CIMT Poster Awards for junior researchers. Develops T-cell receptor based immunotherapies.
• Society for Immunotherapy of Cancer (SITC)majorStrategic or Co-development PartnerPartnership with SITC for 23rd CIMT Annual Meeting (2026). SITC is the leading global organization dedicated to cancer immunotherapy.
• Human Vaccines & ImmunotherapeuticsmajorStrategic or Co-development PartnerPublishing partner for CIMT Annual Meeting reports. Meeting reports are published in Human Vaccines & Immunotherapeutics journal.
• BioMindzminorGTM or Marketing PartnerIcebreaker Event Sponsor of 23rd CIMT Annual Meeting (2026).
• Becton DickinsonmajorGTM or Marketing PartnerSilver sponsor of 23rd CIMT Annual Meeting (2026). Provides flow cytometry and cell analysis technologies for immunology research.
• ACIR (Cancer Immunotherapy)majorStrategic or Co-development PartnerACIR provides free weekly synopses of key advances in cancer immunotherapy and publishes special meeting reports covering CIMT Annual Meetings. ACIR mission is to accelerate advancement of cancer immunotherapy by providing readily accessible information.
• CIMT Immunoguiding Program (CIP)coreStrategic or Co-development PartnerCIMT working group addressing immunoguiding standards for consistent and reproducible immune monitoring in cancer immunotherapy clinical trials.
• CIMT Regulatory Research Group (RRG)coreStrategic or Co-development PartnerCIMT working group addressing the regulatory environment for new immunotherapies, facilitating translation of scientific knowledge from bench to bedside.
• MIATA (Minimal Information About T cell Assays)majorStrategic or Co-development PartnerCIMT-supported reporting framework that enables objective and thorough interpretation of published results from T-cell assays, promoting standardization in the field.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• American Society of Clinical Oncology (ASCO): The world's largest oncology professional organization, hosting the ASCO Annual Meeting. A broad incumbent competing for clinician attention and industry sponsorship in oncology, including immunotherapy content.
• European Hematology Association (EHA): European hematology professional organization hosting the EHA Congress. Adjacent incumbent with overlapping scientific audience in immuno-hematology and cell therapy research.
• British Society for Immunology (BSI): U.K.-based immunology membership organization hosting immunology congresses and educational programs. A broader incumbent competing in the European immunology convening space, though not specialized in cancer immunotherapy.
• European Society for Medical Oncology (ESMO): Europe's leading professional oncology organization hosting the ESMO Congress. A broad incumbent whose meetings include significant immunotherapy content and overlap with CIMT's clinician audience.
• American Association for Cancer Research (AACR): One of the world's largest cancer research organizations, hosting major annual meetings with substantial immunotherapy content. A broader incumbent that overlaps with CIMT's audience but operates at a much larger scale and across all cancer research, not just immunotherapy.

Direct peers

• European Network for Cancer Immunotherapy (ENCI): European counterpart organization co-organizing CICON with CIMT and CRI. Directly comparable mission and audience — ENCI serves the same European cancer immunotherapy research community and runs parallel convening activities.
• Cancer Research Institute (CRI): U.S.-based non-profit that funds cancer immunotherapy research and co-organizes the CICON international conference with CIMT and ENCI. Directly comparable as a cancer-immunotherapy-focused non-profit providing education, funding, and convening.
• Keystone Symposia: Non-profit scientific conference organizer running high-caliber, small-scale research conferences across biomedical fields including immunology. Directly comparable as a non-profit association model organizing scientific meetings on similar topics.
• Cold Spring Harbor Laboratory Meetings: Long-running organizer of invited scientific conferences in molecular biology, immunology, and cancer research. Comparable as a non-profit scientific conference platform serving similar immunology/cancer research audiences.
• Society for Immunotherapy of Cancer (SITC): The leading global organization dedicated to cancer immunotherapy research and education. SITC is a direct peer to CIMT in mission (both organize conferences, publish, and support immuno-oncology research) and is also a formal partner — making it the most directly comparable rival/conference organizer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cancerimmunotherapy
• Xx.com/c_imt
• Facebookfacebook.com/cimtmainz

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancer Immunotherapy